Literature DB >> 10789959

A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis.

T Berghmans1, M Paesmans, J J Body.   

Abstract

The frequency of hyponatraemia varies from less than 1% to more than 40% in series reported from general hospitals. We performed a prospective study to evaluate its incidence and to determine the types of hyponatraemia in a dedicated cancer hospital. All patients admitted to the Department of Medicine were prospectively studied over 11 months. Hyponatraemia was defined as a serum Na level < or =130 mEq/l. Urine and blood samples were collected at baseline, and all consecutive hyponatraemic episodes were studied. One hundred and six patients developed 123 episodes of hyponatraemia. The observed incidence of hyponatraemia was 3.7%. Sodium depletion and syndrome of inappropriate antidiuretic hormone secretion (SIADH) each accounted for almost one third of all aetiologies. Serum urea and uric acid, urinary Na and fractional excretions of Na and urea were most useful for the differential diagnosis. The percentage of deaths observed in the hyponatraemic group, 19.5%, was higher than in the whole cancer population (6.3%) although no death was apparently due directly to hyponatraemia. Hyponatraemia is regularly diagnosed in cancer patients, but it was related to SIADH in only about one third of the cases. A higher mortality was observed in hyponatraemic patients than in normonatraemic patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10789959     DOI: 10.1007/s005200050284

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  43 in total

1.  Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.

Authors:  R Berardi; M Caramanti; I Fiordoliva; F Morgese; A Savini; S Rinaldi; M Torniai; M Tiberi; C Ferrini; M Castagnani; F Rovinelli; A Onofri; S Cascinu
Journal:  Support Care Cancer       Date:  2014-08-21       Impact factor: 3.603

2.  Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM).

Authors:  E Sbardella; A M Isidori; G Arnaldi; M Arosio; C Barone; A Benso; R Berardi; G Capasso; M Caprio; F Ceccato; G Corona; S Della Casa; L De Nicola; M Faustini-Fustini; E Fiaccadori; L Gesualdo; S Gori; A Lania; G Mantovani; P Menè; G Parenti; C Pinto; R Pivonello; P Razzore; G Regolisti; C Scaroni; F Trepiccione; A Lenzi; A Peri
Journal:  J Endocrinol Invest       Date:  2017-11-20       Impact factor: 4.256

Review 3.  Hyponatraemia: more than just a marker of disease severity?

Authors:  Robert W Schrier; Shailendra Sharma; Dmitry Shchekochikhin
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

4.  Hyponatremia as an independent prognostic factor in patients with terminal cancer.

Authors:  Johi Yoon; Seo Hee Ahn; Yong Joo Lee; Chul-Min Kim
Journal:  Support Care Cancer       Date:  2014-11-30       Impact factor: 3.603

5.  Hyponatremia associated with Ipilimumab-induced hypophysitis.

Authors:  Zachary R Barnard; Brian P Walcott; Kristopher T Kahle; Brian V Nahed; Jean Valery Coumans
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

6.  Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients.

Authors:  R Berardi; M Caramanti; M Castagnani; S Guglielmi; F Marcucci; A Savini; F Morgese; S Rinaldi; C Ferrini; M Tiberi; M Torniai; F Rovinelli; I Fiordoliva; A Onofri; S Cascinu
Journal:  Support Care Cancer       Date:  2015-03-05       Impact factor: 3.603

7.  Association of serum sodium with morbidity and mortality in hospitalized patients undergoing major orthopedic surgery.

Authors:  Finnian R Mc Causland; John Wright; Sushrut S Waikar
Journal:  J Hosp Med       Date:  2014-02-13       Impact factor: 2.960

8.  Predictors of inpatient mortality in an acute palliative care unit at a comprehensive cancer center.

Authors:  Ahmed Elsayem; Masanori Mori; Henrique A Parsons; Mark F Munsell; David Hui; Marvin O Delgado-Guay; Timotheos Paraskevopoulos; Nada A Fadul; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2009-04-07       Impact factor: 3.603

9.  Copeptin as a marker for arginine-vasopressin/antidiuretic hormone secretion in the diagnosis of paraneoplastic syndrome of inappropriate ADH secretion.

Authors:  A Wuttke; K C Dixit; G Szinnai; S C Werth; U Haagen; M Christ-Crain; N Morgenthaler; G Brabant
Journal:  Endocrine       Date:  2013-03-12       Impact factor: 3.633

10.  Mortality after hospitalization with mild, moderate, and severe hyponatremia.

Authors:  Sushrut S Waikar; David B Mount; Gary C Curhan
Journal:  Am J Med       Date:  2009-09       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.